Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Eligibility Criteria

• * Patients with neoplastic hematological disorders with indication of allogeneic transplant according to the National Comprehensive Cancer Network (NCCN) or other standard guidelines as follows:
• * Acute myeloid leukemia \[AML\] in morphologic complete remission with intermediate/high-risk features (per NCCN criteria) or relapsed disease
• * Chronic myeloid leukemia \[CML\] in any chronic phase.
• * Myelodysplastic syndrome \[MDS\] with intermediate/high risk features or refractory disease (with bone marrow blast count \<10%).
• * Acute lymphoblastic leukemia \[ALL\] in morphologic complete remission with high-risk features or relapsed disease.
• * Negative test for donor-specific antibody within 28 days of starting conditioning regimen.
• * Age Criteria: 19-65 years.
• * Organ Function Criteria: The following organ function testing should be done within 35 days before study registration.
• * Cardiac: Normal left ventricular ejection fraction (LVEF) (50% or above) as measured by MUGA or Echocardiogram.
• * Pulmonary: FVC, FEV1 and DLCO (corrected) should be 50% or above of expected.
• * Renal: serum creatinine level to be \<2 mg/dl AND estimated (Cockcroft-Gault formula) or measured (takes priority if done) creatinine clearance (CrCl) must be equal or greater than 70 mL/min/1.73 m2.
• * Hepatic: serum bilirubin 1.5 upper limit of normal (ULN), Aspartate transaminase (AST)/alanine transaminase (ALT) 2.5 ULN, and alkaline phosphatase 2.5 ULN.
• * Performance status: Karnofsky performance score (KPS) or Lansky score: ≥80.
• * Hematopoietic cell transplant comorbidity index (HCT-CI) \<3. Exception may be made on individual cases after discussion with the primary investigator.
• * Consent: All patients must be informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines.
• * Absence of uncontrolled infection with sepsis syndrome (e.g persistent positive blood culture).
• * NO hemodynamic instability (due to sepsis or organ dysfunction) or circulatory volume overload.
• * NO clinically significant organ toxicity that are defined as follows:
• * Heart failure with subnormal LVEF or clinical fluid overload.
• * Elevated serum creatinine or subnormal creatinine clearance (either estimated or measured).
• * Elevated total bilirubin ≥1.5 upper normal level (unless indirect hyperbilirubinemia attributed to non-hepatic pathology), or elevated liver enzymes (ALT, AST, ALP) \>5 x ULN.
• * Hypoxemia requiring oxygen therapy
• * NO acute graft versus host disease (any grade).
• * Neutrophil engraftment.
• * Non-compliant patients.
• * No appropriate caregivers identified.
• * Uncontrolled medical or psychiatric disorders which may preclude patients to undergo clinical studies (Discretion of the attending physician).
• * Active central nervous system (CNS) neoplastic involvement.
• * Morbid obesity with body mass index \>35 (borderline cases may be considered on case-by-case basis after discussion with the primary investigator).
• * Patients with known allergy to DMSO.
• * HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive.
• * Pregnant or breastfeeding women.